Table 8. RR and AR of second malignancy... | American Society of Hematology

Table 8.

RR and AR of second malignancy by overall treatment exposure in 961 patients with more than 10 years of potential follow-up

Initial therapy	No.	PY	O	E	RR	(95% CI)	AR
All patients
CMT^8-150	296	4 046	53	8.6	6.1^8-151	(4.7, 8.0)	109.7
RT	665	10 302	109	26.9	4.0^8-151	(3.4, 4.9)	79.6
Nonrelapsed cases
CMT	256	3 739	48	8.2	5.9^8-152	(4.2, 7.7)	106.5
RT	492	7 997	79	21.2	3.7^8-152	(3.0, 4.6)	72.3
Relapsed cases
Relapsed after CMT	40	307	5	0.4	11.3^8-153	(3.7, 26.3)	148.2
Relapsed after RT	173	2 305	30	5.8	5.2^8-153	(3.5, 7.2)	105.1

Initial therapy	No.	PY	O	E	RR	(95% CI)	AR
All patients
CMT^8-150	296	4 046	53	8.6	6.1^8-151	(4.7, 8.0)	109.7
RT	665	10 302	109	26.9	4.0^8-151	(3.4, 4.9)	79.6
Nonrelapsed cases
CMT	256	3 739	48	8.2	5.9^8-152	(4.2, 7.7)	106.5
RT	492	7 997	79	21.2	3.7^8-152	(3.0, 4.6)	72.3
Relapsed cases
Relapsed after CMT	40	307	5	0.4	11.3^8-153	(3.7, 26.3)	148.2
Relapsed after RT	173	2 305	30	5.8	5.2^8-153	(3.5, 7.2)	105.1

PY indicates person-years; O, observed; E, expected; RR, relative risk; CI, confidence interval; AR, absolute excess risk; CMT, combined modality therapy; RT, radiation therapy.

F8-150

90% of patients who received CMT were treated with alkylating agent–containing regimens.

P = .015.

P = .016.

P = .19.

This Feature Is Available To Subscribers Only